氟桂利嗪联合丹参多酚酸盐在偏头痛患者中的应用及对VAS评分的影响研究

Application of Flunarizine Combined with Danshen Polyphenolate in Migraine Patients and Its Influence on VAS Score

目的探讨氟桂利嗪联合丹参多酚酸盐在偏头痛患者中的临床效果及对VAS评分的影响。方法选择2016年5月—2018年4月治疗的偏头痛患者68例作为对象,随机数字表分为对照组(n=34)和观察组(n=34)。两组均给予常规方法治疗,对照组采用氟桂利嗪胶囊治疗,观察组联合丹参多酚酸治疗,比较两VAS评分及药物安全性。结果观察组护理后1、2、3周VAS评分,均低于对照组(t=6.361、12.109、10.442,P<0.05);两组治疗期间安全性比较差异无统计学意义(χ~2=1.214,P=0.582)。结论氟桂利嗪联合丹参多酚酸盐用于偏头痛患者中能降低患者VAS评分,药物安全性较高,值得推广应用。

Objective To investigate the clinical effects of flunarizine combined with salvianolate in patients with migraine and the effect on VAS score. Methods Sixty-eight patients with migraine treated from May 2016 to April 2018 were enrolled. The random number table was divided into control group(n=34) and observation group(n=34). Both groups were treated with conventional methods. The control group was treated with flunarizine capsules. The observation group was treated with Danshen polyphenolic acid to compare the two VAS scores and drug safety. Results The VAS scores of the observation group at 1 week, 2 weeks, and 3 weeks after treatment were lower than those of the control group(t=6.361, 12.109, 10.442, P<0.05). There was no statistically significant safety between the two groups during treatment(χ^2=1.214, P=0.582). Conclusion Flunarizine combined with Danshen polyphenolate can reduce VAS score in patients with migraine, and the drug safety is high, which is worthy of popularization and application.